Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorCarvajal, Silvia
dc.contributor.authorPerramón, Meritxell
dc.contributor.authorOró, Denise
dc.contributor.authorCasals, Eudald
dc.contributor.authorFernández-Varo, Guillermo
dc.contributor.authorCasals, Gregori
dc.contributor.authorFranco Puntes, Victor
dc.date.accessioned2020-03-17T09:25:37Z
dc.date.available2020-03-17T09:25:37Z
dc.date.issued2019-09-06
dc.identifier.citationCarvajal S, Perramón M, Oró D, Casals E, Fernández-Varo G, Casals G, et al. Cerium oxide nanoparticles display antilipogenic effect in rats with non-alcoholic fatty liver disease. Sci Rep. 2019 Sep 6;9:12848.
dc.identifier.issn2045-2322
dc.identifier.urihttp://hdl.handle.net/11351/4734
dc.descriptionCerium oxide nanoparticles; Non-alcoholic fatty liver disease; Antioxidant agent
dc.description.abstractNon-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide, ranging from steatosis to non-alcoholic steatohepatitis (NASH). Recently, cerium oxide nanoparticles (CeO2NPs) have emerged as a new antioxidant agent with hepatoprotective properties in experimental liver disease. The aim of the current investigation was to elucidate whether CeO2NPs display beneficial effects in an experimental model of NAFLD.Therefore, fifteen Wistar rats were subjected to a methionine and choline deficient diet (MCDD) for 6 weeks and intravenously treated with CeO2NP or vehicle during the weeks three and four of the diet. The effect of CeO2NPs on serum biochemistry, hepatic steatosis, inflammation, fatty acid content and expression of reactive oxygen species (ROS) and lipid metabolism related genes was assessed. MCDD fed rats showed increased inflammation, enhanced hepatic lipid accumulation of both saturated and unsaturated fatty acids (FAs) and overexpression of genes related to fatty liver and ROS metabolism. Treatment with CeO2NPs was able to reduce the size and content of hepatocyte lipid droplets, the hepatic concentration of triglyceride- and cholesterol ester-derived FAs and the expression of several genes involved in cytokine, adipokine and chemokine signaling pathways. These findings suggest that CeO2NPs could be of beneficial value in NAFLD.
dc.language.isoeng
dc.publisherNature Publishing Group
dc.relation.ispartofseriesScientific Reports;9
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectEsteatosi hepàtica
dc.subjectNanopartícules
dc.subjectAntioxidants
dc.subject.meshMetal Nanoparticles
dc.subject.meshNon-alcoholic Fatty Liver Disease
dc.subject.meshFree Radical Scavengers
dc.titleCerium oxide nanoparticles display antilipogenic effect in rats with non-alcoholic fatty liver disease
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1038/s41598-019-49262-2
dc.subject.decsnanopartículas metálicas
dc.subject.decsesteatosis hepática no alcohólica
dc.subject.decsdepuradores de radicales libres
dc.relation.publishversionhttps://www.nature.com/articles/s41598-019-49262-2
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.authoraffiliation[Carvajal S, Perramón M, Oró D] Biochemistry and Molecular Genetics Service, Hospital Clínic Universitari, IDIBAPS, Barcelona, Spain. Centro de Investigación Biomédica en Red en el Área temática de Enfermedades Hepáticas (CIBEREHD), Madrid, Spain. [Casals E] School of Biotechnology and Health Sciences, Wuyi University, Jiangmen, China. [Fernández-Varo G] Biochemistry and Molecular Genetics Service, Hospital Clínic Universitari, IDIBAPS, Barcelona, Spain. Centro de Investigación Biomédica en Red en el Área temática de Enfermedades Hepáticas (CIBEREHD), Madrid, Spain. Department of Biomedicine, University of Barcelona, Barcelona, Spain. [Casals G] Biochemistry and Molecular Genetics Service, Hospital Clínic Universitari, IDIBAPS, Barcelona, Spain. Centro de Investigación Biomédica en Red en el Área temática de Enfermedades Hepáticas (CIBEREHD), Madrid, Spain. Working group for the biochemical assessment of hepatic disease-SEQCML, Barcelona, Spain. [Puntes V] Institut Català de Recerca i Estudis Avançats, (ICREA), Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Institut Català de Nanociència i Nanotecnologia (ICN2), Universitat Autònoma de Barcelona, Bellaterra, Spain
dc.identifier.pmid31492960
dc.identifier.wos000484656700036
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record